Evidence from credible sources supports the statement as accurate. Learn more in Methodology.
The proposed acquisition of JenaValve by Edwards Lifesciences was halted (blocked) by the FTC/court action.
On January 9, 2026 the U.S. District Court for the District of Columbia granted the FTC’s request for a preliminary injunction preventing Edwards Lifesciences from acquiring JenaValve, according to an FTC press release. Edwards announced it will not acquire JenaValve following the court order, and reporting from Reuters and industry outlets confirmed the court blocked the deal. Verdict: True — primary (FTC) and company statements and independent news reporting show the FTC halted the proposed acquisition and Edwards abandoned the transaction.